ArticleEye and vision (London, England)2025
Two-year results of Lenslet-ARray-Integrated spectacle lenses for myopia control in children.
Article in Eye and vision (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Two-Year Changes in Astigmatism in Myopic Children Wearing Lenslet-ARray-Integrated Spectacle Lenses.Ophthalmology science · 2026Article
- Spectacle lenses for control of myopia progression in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- What a Lens Imposes and What a Child Sees Are Not the Same Thing.Investigative ophthalmology & visual science · 2026Article
- Effect of combining peripheral defocus spectacle lens wear with 0.01% atropine.Annals of translational medicine · 2026Article
- Comparative Effectiveness of Three Myopia Control Lenses: A Multicenter, Real-World Study of 5182 Adolescents and Children in Chongqing, China.Translational vision science & technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo investigate the 2-year myopia control efficacy of Lenslet-ARray-Integrated (LARI) lenses with positive (PLARI) and negative (NLARI) power lenslets and the effect of switching lens designs.
methodsA total of 218 children, who were randomly assigned to wear PLARI, NLARI, or single-vision (SV) lenses in Phase 1 continued in this randomized, double-masked extended trial for an additional year (Phase 2). Participants were randomly assigned to one of six groups: SV to PLARI, SV to NLARI, PLARI to PLARI (P-PLARI), PLARI to NLARI (P-NLARI), NLARI to PLARI (N-PLARI), and NLARI to NLARI (N-NLARI). In year 2, the change in spherical equivalent refraction (SER) and axial elongation (AE) from the SV group were extrapolated based on published data [the extrapolated single vision (ESV) group]. Linear models were used to determine differences in SER changes and AE among groups in 2 years and in Phase 2 only.
resultsAfter 2 years, the SER changes (- 0.87 ± 0.68 D, - 0.64 ± 0.86 D, - 0.68 ± 0.54 D, and - 0.75 ± 0.62 D, respectively) and AE (0.44 ± 0.33 mm, 0.33 ± 0.32 mm, 0.36 ± 0.23 mm, and 0.39 ± 0.25 mm, respectively) of P-PLARI, P-NLARI, N-PLARI, and N-NLARI were significantly smaller than those in the ESV group (SER: - 1.24 ± 0.77 D, all P < 0.05; AE: 0.63 ± 0.33 mm, all P < 0.001). In Phase 2, there was no significant difference in SER changes among the four LARI groups and ESV group (P = 0.58). In Phase 2, AE of the P-NLARI and N-PLARI groups was significantly smaller than the ESV group (P < 0.001 and P = 0.001), and AE of the P-PLARI and N-NLARI groups were slightly smaller than that of ESV group (P = 0.054 and P = 0.10), but there were no significant differences in AE among the four LARI groups (all P > 0.05).
conclusionsWearing LARI lenses for 2 years effectively slowed myopia progression and AE. Switching to another LARI design after 1 year improved myopia control efficacy, in terms of AE, during the second year, but not SER progression.
trial registrationChinese Clinical Trial Registry, ChiCTR2200057210. Registered 03 March 2022, https://www.chictr.org.cn/bin/project/edit?pid=152900 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.